154 related articles for article (PubMed ID: 9215796)
1. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) in high grade malignant gliomas.
Lambin P; Poortmans P; Menten J; Hamers HP
Radiother Oncol; 1997 Jun; 43(3):324. PubMed ID: 9215796
[No Abstract] [Full Text] [Related]
2. Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme.
Simon JM; Noël G; Chiras J; Hoang-Xuan K; Delattre JY; Baillet F; Mazeron JJ
Radiother Oncol; 2003 Apr; 67(1):45-51. PubMed ID: 12758239
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide.
Droller MJ
J Urol; 2000 May; 163(5):1600. PubMed ID: 10798919
[No Abstract] [Full Text] [Related]
4. Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide.
Bussink J; Kaanders JH; Van der Kogel AJ
Acta Oncol; 1999; 38(7):875-82. PubMed ID: 10606417
[TBL] [Abstract][Full Text] [Related]
5. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
Bernier J; Denekamp J; Rojas A; Minatel E; Horiot J; Hamers H; Antognoni P; Dahl O; Richaud P; van Glabbeke M; Piérart M
Radiother Oncol; 2000 May; 55(2):111-9. PubMed ID: 10799722
[TBL] [Abstract][Full Text] [Related]
6. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
Kaanders JH; Pop LA; Marres HA; Liefers J; van den Hoogen FJ; van Daal WA; van der Kogel AJ
Radiother Oncol; 1998 Aug; 48(2):115-22. PubMed ID: 9783882
[TBL] [Abstract][Full Text] [Related]
7. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas.
van der Maazen RW; Thijssen HO; Kaanders JH; de Koster A; Keyser A; Prick MJ; Grotenhuis JA; Wesseling P; van der Kogel AJ
Radiother Oncol; 1995 May; 35(2):118-22. PubMed ID: 7569019
[TBL] [Abstract][Full Text] [Related]
8. Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy.
Rojas A; Joiner MC; Denekamp J
Radiother Oncol; 1992 Jun; 24(2):123-4. PubMed ID: 1386678
[No Abstract] [Full Text] [Related]
9. Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment.
Fatigante L; Ducci F; Cartei F; Colosimo S; Marini C; Prediletto R; Danesi R; Laddaga M; Del Tacca M; Caciagli P
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):499-504. PubMed ID: 9112444
[TBL] [Abstract][Full Text] [Related]
10. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Takes RP; de Bree R; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
Clin Cancer Res; 2014 Mar; 20(5):1345-54. PubMed ID: 24452791
[TBL] [Abstract][Full Text] [Related]
11. Carbogen and nicotinamide: expectations too high?
Brown JM
Radiother Oncol; 1992 Jun; 24(2):75-6. PubMed ID: 1386679
[No Abstract] [Full Text] [Related]
12. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ; Rojas AM; Phillips H; Saunders MI
Cancer; 2005 Jun; 103(11):2287-97. PubMed ID: 15834926
[TBL] [Abstract][Full Text] [Related]
13. Carbogen and nicotinamide: expectations too high? (response to J. Martin Brown).
Horsman MR
Radiother Oncol; 1992 Jun; 24(2):121-2. PubMed ID: 1386677
[No Abstract] [Full Text] [Related]
14. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.
Saunders M; Dische S
Br J Cancer Suppl; 1996 Jul; 27():S271-8. PubMed ID: 8763896
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules.
Rojas A; Vojnovic B; Johns H; Joiner MC; Martindale C; Fowler JF; Denekamp J
Radiother Oncol; 1996 Apr; 39(1):53-64. PubMed ID: 8735494
[TBL] [Abstract][Full Text] [Related]
16. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
[TBL] [Abstract][Full Text] [Related]
17. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
Hoskin PJ; Rojas AM; Saunders MI; Bentzen SM; Motohashi KJ;
Radiother Oncol; 2009 Apr; 91(1):120-5. PubMed ID: 18992952
[TBL] [Abstract][Full Text] [Related]
18. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
Janssens GO; van Bockel LW; Doornaert PA; Bijl HP; van den Ende P; de Jong MA; van den Broek GB; Verbist BM; Terhaard CH; Span PN; Kaanders JH
Eur J Cancer; 2014 Apr; 50(6):1112-9. PubMed ID: 24424106
[TBL] [Abstract][Full Text] [Related]
19. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
Hoskin PJ; Saunders MI; Phillips H; Cladd H; Powell ME; Goodchild K; Stratford MR; Rojas A
Br J Cancer; 1997; 76(2):260-3. PubMed ID: 9231929
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
